What is Zacks Research’s Forecast for Novavax Q1 Earnings?

Novavax, Inc. (NASDAQ:NVAX) – Investment analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for shares of Novavax in a research note issued on Wednesday, February 26th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will post earnings per share of ($0.65) for the quarter, down from their previous forecast of ($0.63). The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. Zacks Research also issued estimates for Novavax’s Q2 2025 earnings at $0.38 EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.83) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.00 EPS and FY2026 earnings at $0.31 EPS.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same period in the previous year, the business earned ($1.44) earnings per share.

A number of other brokerages have also issued reports on NVAX. BTIG Research started coverage on Novavax in a research note on Friday. They set a “buy” rating and a $19.00 price target for the company. TD Cowen raised Novavax to a “hold” rating in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $18.00.

Novavax Stock Performance

Shares of NVAX stock opened at $8.33 on Monday. Novavax has a 52-week low of $3.81 and a 52-week high of $23.86. The firm has a market capitalization of $1.33 billion, a P/E ratio of -3.69, a P/E/G ratio of 2.85 and a beta of 2.14. The stock has a 50 day moving average price of $8.51 and a 200 day moving average price of $9.96.

Institutional Trading of Novavax

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Novavax by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company’s stock valued at $126,439,000 after purchasing an additional 296,181 shares during the last quarter. Shah Capital Management lifted its holdings in shares of Novavax by 13.6% in the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock valued at $89,637,000 after buying an additional 1,333,305 shares during the period. State Street Corp lifted its holdings in shares of Novavax by 26.7% in the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after buying an additional 1,621,772 shares during the period. Sanofi purchased a new stake in shares of Novavax in the fourth quarter worth about $55,319,000. Finally, Geode Capital Management LLC grew its holdings in Novavax by 4.4% during the fourth quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company’s stock worth $29,415,000 after acquiring an additional 155,206 shares during the period. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Insider Buying and Selling

In related news, Director Rachel K. King sold 4,150 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the transaction, the director now directly owns 14,770 shares in the company, valued at $133,225.40. The trade was a 21.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James F. Young sold 5,400 shares of the business’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the transaction, the director now owns 51,760 shares in the company, valued at approximately $414,080. This trade represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock worth $119,641 in the last ninety days. 1.00% of the stock is owned by insiders.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.